(12) **Translation of European patent specification**

(11) **NO/EP 3706739 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 31/428 (2006.01)	***A61K 31/427 (2006.01)***	***A61P 35/00 (2006.01)***
A61K 9/20 (2006.01)	***A61K 31/4985 (2006.01)***	***C07D 277/82 (2006.01)***
A61K 9/48 (2006.01)	***A61P 25/14 (2006.01)***	***C07D 417/12 (2006.01)***

Norwegian Industrial Property Office

(45)	Translation Published	2025.01.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.10.16
(86)	European Application Nr.	18876779.2
(86)	European Filing Date	2018.11.11
(87)	The European Application's Publication Date	2020.09.16
(30)	Priority	2017.11.12, US, 201762584856 P 2018.08.13, US, 201862717948 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
	Designated validation states	MD
(73)	Proprietor	Biohaven Therapeutics Ltd., 215 Church Street, New Haven, CT 06510, USA
(72)	Inventor	CORIC, Vladimir, 215 Church Street, New Haven Connecticut 06510, USA BERMAN, Robert, 215 Church Street, New Haven Connecticut 06510, USA BEINER, Melissa, 215 Church Street, New Haven Connecticut 06510, USA L'ITALIEN, Gilbert, 215 Church Street, New Haven Connecticut 06510, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **USE OF RILUZOLE PRODRUGS TO TREAT ATAXIAS**

(56) References Cited:

WO-A2-2016/140878, US-A1- 2014 371 208, WO-A1-2016/140879,

ROMANO SILVIA ET AL: "Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial - Supplementary webappendix", THE LANCET NEUROLOGY, vol. 14, no. 10, 1 October 2015 (2015-10-01), AMSTERDAM, NL, pages 985 - 991, XP093081817, ISSN: 1474-4422, Retrieved from the Internet <URL:https://ars.els-cdn.com/content/image/1-s2.0-S147444221500201X-mmc1.pdf> DOI: 10.1016/S1474-4422(15)00201-X

ROMANO SILVIA ET AL: "Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial", THE LANCET NEUROLOGY, 26 August 2015 (2015-08-26), pages 985 - 991, XP055815706, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S147444221500201X?via%3Dihub> [retrieved on 20210618], DOI: 10.1016/S1474-4422(15)00201-X

ANONYMOUS: "History of Changes for Study: NCT02960893-Trial in Adult Subjects With Spinocerebellar Ataxia", CLINICAL TRIALS.GOV, 8 November 2016 (2016-11-08), XP055607551, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT02960893?V_1=View#StudyPageTop> [retrieved on 20181212]

ANONYMOUS: "Analysis of 96 Week, Long-Term Open Label Extension Phase of Study BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia", NEUROLOGY, 96 (15 SUPPLEMENT), 17 April 2021 (2021-04-17), pages 1 - 7, XP093082171, Retrieved from the Internet <URL:https://n.neurology.org/content/96/15_Supplement/2837> [retrieved on 20230914]

Patentkrav

1. En riluzol-prodroge for anvendelse i behandlingen av ataksi i en pasient med behov for det, hvor

ataksien er spinocerebellær ataksi valgt fra SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 og SCA10; og

riluzol-prodrogen er i henhold til den følgende formelen:



og et farmasøytisk akseptabelt salt derav, hvor:

R_{23} er valgt fra gruppen som består av H, CH_3, CH_2CH_3, $CH_2CH_2CH_3$, CH_2CCH, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2OH, CH_2OCH_2Ph, $CH_2CH_2OCH_2Ph$, $CH(OH)CH_3$, CH_2Ph, CH_2(sykloheksyl), CH_2(4-OH-Ph), $(CH_2)_4NH_2$, $(CH_2)_3NHC(NH_2)NH$, CH_2(3-indol), CH_2(5-imidazol), CH_2CO_2H, $CH_2CH_2CO_2H$, CH_2CONH_2, og $CH_2CH_2CONH_2$.

2. Riluzol-prodrogen for anvendelse i henhold til krav 1, hvor ataksien er en ataksi assosiert med translaterte GAG-gjentatte ekspansjoner.

3. Riluzol-prodrogen for anvendelse i henhold til krav 1, hvor ataksien er en ataksi assosiert med ikke-translaterte gjentatte ekspansjoner i ikke-kodende områder.

4. Riluzol-prodrogen for anvendelse i henhold til et hvilket som helst av de foregående kravene, hvor riluzol-prodrogen har den følgende formelen:



5. Et sett for anvendelse i behandlingen av en pasient rammet av ataksi, hvor ataksien er spinocerebellær ataksi valgt fra SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 og SCA10, hvor settet omfatter:

(a) en riluzol-prodroge som har den følgende formelen:



eller et farmasøytisk akseptabelt salt derav, hvor:

R_{23} er valgt fra gruppen som består av H, CH_3, CH_2CH_3, $CH_2CH_2CH_3$, CH_2CCH, $CH(CH_3)_2$, $CH_2CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$, CH_2OH, CH_2OCH_2Ph, $CH_2CH_2OCH_2Ph$, $CH(OH)CH_3$, CH_2Ph, CH_2(sykloheksyl), CH_2(4-OH-Ph), $(CH_2)_4NH_2$, $(CH_2)_3NHC(NH_2)NH$, CH_2(3-indol), CH_2(5-imidazol), CH_2CO_2H, $CH_2CH_2CO_2H$, CH_2CONH_2, og $CH_2CH_2CONH_2$; og

(b) et annet terapeutisk middel.

6. Settet for anvendelse ifølge krav 5, hvor riluzol-prodrogen har den følgende formelen: